产品
编 号：F743329
分子式：C20H25N5O3
分子量：383.44
分子式：C20H25N5O3
分子量：383.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1228012-18-7
产品详情
生物活性：
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo.
体内研究：
CC214-2 (25 mg/kg，50 mg/kg；口服；每天一次，持续 21 天) 导致 PC3 肿瘤异种移植模型中的肿瘤体积减小。CC214-2 (30 mg/kg，100 mg/kg；口服；单次剂量) 在体内分别抑制 mTORC1 (pS6) 和 mTORC2 (pAktS473) 至少 8 小时和 24 小时。CC214-2 (30 毫克/千克；口服) 减少结核杆菌 CFU 数量和预防慢性结核感染小鼠的死亡率。CC214-2 (50 mg/kg；口服；每天一次，持续 6 天) 显着降低小鼠 U87EGFRvIII 侧腹异种移植物的生长。CC214-2 (100 mg/kg；口服；每 2 天一次，持续 6 天) 抑制颅内胶质母细胞瘤模型中的 mTORC1 和 mTORC2 信号传导。Animal Model:U87EGFRvIII flank xenografts in mice
Dosage:50 mg/kg
Administration:PO; once daily for 6 days
Result:Inhibited tumor growth.Similarly activated autophagy in U87EGFRvIII xenografts.
CC214-2 is an oral active and selective mTOR kinase inhibitor. CC214-2 targets to both of mTORC1 (pS6) and mTORC2 (pAktS473). CC214-2 induces autophagy, which is a potential target for host-directed therapy (HDT) in tuberculosis. CC214-2 exhibits synergistic bactericidal and sterilizing activity agasinst tuberculosis (TB), and shortens the treatment duration. CC214-2 also inhibits Rapamycin (HY-10219)-resistant signaling and the growth of glioblastomas in vitro and in vivo.
体内研究：
CC214-2 (25 mg/kg，50 mg/kg；口服；每天一次，持续 21 天) 导致 PC3 肿瘤异种移植模型中的肿瘤体积减小。CC214-2 (30 mg/kg，100 mg/kg；口服；单次剂量) 在体内分别抑制 mTORC1 (pS6) 和 mTORC2 (pAktS473) 至少 8 小时和 24 小时。CC214-2 (30 毫克/千克；口服) 减少结核杆菌 CFU 数量和预防慢性结核感染小鼠的死亡率。CC214-2 (50 mg/kg；口服；每天一次，持续 6 天) 显着降低小鼠 U87EGFRvIII 侧腹异种移植物的生长。CC214-2 (100 mg/kg；口服；每 2 天一次，持续 6 天) 抑制颅内胶质母细胞瘤模型中的 mTORC1 和 mTORC2 信号传导。Animal Model:U87EGFRvIII flank xenografts in mice
Dosage:50 mg/kg
Administration:PO; once daily for 6 days
Result:Inhibited tumor growth.Similarly activated autophagy in U87EGFRvIII xenografts.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备